This new technology could one day significantly expand the market for gene-editing biotechs.

One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your ...

The company's innovative qualities may pay rich dividends down the road.

The speed at which a cell produces proteins is a decisive factor in determining whether it divides, specializes or retains ...

Learn how gene editing is transforming sickle cell disease treatment and why expanding access to younger children matters.

AI-guided CRISPR screening found two overlooked psoriasis targets, with topical gels reducing skin inflammation in mice as ...

There's more to young biopharma companies than their numbers, but those numbers are still an important part of each ...

A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...

Researchers are investigating the potential of CRISPR in relation to Down syndrome.

Biohub researchers have performed what they believe is the first genome-wide CRISPR study of primary human adult skin cells, ...

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.

A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...